Trial Profile
A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FIRST
- Sponsors AstraZeneca
- 16 May 2019 This trial has been completed in UK as per European Clinical Trials Database record
- 14 Nov 2018 Results assessing the effectiveness and cost of fulvestrant versus anastrozole from FIRST and FALCON trials, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 09 Dec 2017 Results of FALCON, FIRST and CONFIRM studies comparing treatment effect of Fulvestrant vs comparators in post-menopausal patients, presented at the 40th Annual San Antonio Breast Cancer Symposium.